Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 13, 2025 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases

Initiate a suite of clinical trials in 2025 intended to support global registration of NX-5948 for the treatment of chronic lymphocytic leukemia Expand the development of NX-5948 in additional...
October 26, 2022 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit

Complete response observed and ongoing in a patient with multiply relapsed/refractory diffuse large B cell lymphoma (DLBCL) Dual BTK degradation and immunomodulatory activity achieved by day 8 and...
June 10, 2022 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Will Present Trial in Progress Posters for Two Clinical Programs at the 2022 Annual European Hematology Association (EHA) Congress

SAN FRANCISCO, June 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs,...
May 17, 2022 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas

SAN FRANCISCO, May 17, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that...
March 08, 2022 16:47 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics to Present Preclinical Data from Its Novel BTK Degrader (NX-2127) and CBL-B Inhibitor (NX-0255) Programs at the American Association for Cancer Research Annual Meeting

SAN FRANCISCO, March 08, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinical...